1. Home
  2. CYTK vs RGC Comparison

CYTK vs RGC Comparison

Compare CYTK & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$62.51

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Regencell Bioscience Holdings Limited

RGC

Regencell Bioscience Holdings Limited

HOLD

Current Price

$19.62

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
RGC
Founded
1997
2014
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.4B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
CYTK
RGC
Price
$62.51
$19.62
Analyst Decision
Strong Buy
Analyst Count
16
0
Target Price
$78.94
N/A
AVG Volume (30 Days)
1.7M
238.7K
Earning Date
11-05-2025
10-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$87,211,000.00
N/A
Revenue This Year
$361.33
N/A
Revenue Next Year
$65.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2609.26
N/A
52 Week Low
$29.31
$0.09
52 Week High
$69.33
$83.60

Technical Indicators

Market Signals
Indicator
CYTK
RGC
Relative Strength Index (RSI) 49.62 72.64
Support Level $59.37 $16.30
Resistance Level $63.80 $18.10
Average True Range (ATR) 2.56 1.72
MACD -0.44 0.53
Stochastic Oscillator 42.46 98.55

Price Performance

Historical Comparison
CYTK
RGC

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About RGC Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Share on Social Networks: